1009 related articles for article (PubMed ID: 29232037)
1. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
2. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
3. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
[TBL] [Abstract][Full Text] [Related]
5. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
7. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
8. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Agostino J; Macura KJ; Carter HB; Schaeffer EM; Partin AW; Sokoll LJ; Ross AE
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):228-233. PubMed ID: 28117387
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer.
Chen Y; Xu D; Ruan M; Li H; Lin G; Song G
Investig Clin Urol; 2023 Jul; 64(4):363-372. PubMed ID: 37417561
[TBL] [Abstract][Full Text] [Related]
10. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
11. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
12. Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
Schulze A; Christoph F; Sachs M; Schroeder J; Stephan C; Schostak M; Koenig F
Urol Int; 2020; 104(3-4):181-186. PubMed ID: 32224611
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome.
Ryznarová Z; Keller J; Záleský M; Zachoval R; Čapek V; Malikova H
Neuro Endocrinol Lett; 2019 Mar; 40(1):41-50. PubMed ID: 31184822
[TBL] [Abstract][Full Text] [Related]
14. The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
Cui Y; Zhao J; Sun Y
Urol Int; 2023; 107(10-12):959-964. PubMed ID: 38011845
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
16. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
17. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
[TBL] [Abstract][Full Text] [Related]
19. Utility of serum biomarkers for predicting cancer in patients with previous negative prostate biopsy.
Wang Z; Chan MT; Tsang WC; Chiong E
World J Urol; 2022 Sep; 40(9):2255-2260. PubMed ID: 35821266
[TBL] [Abstract][Full Text] [Related]
20. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
